Grok 4.3

Act as a senior B2B SaaS pricing strategist. Write a board-ready decision memo for Northstar Workflow, which plans to replace bundled plans with per-seat pricing on January 1. Use only the facts below; do not introduce external benchmarks. Current annualized revenue is $8.0M. Customer mix and performance: - Starter: 44% of customers, $1.35M ARR, $39/month for up to 5 seats, average 3 active seats, 2.4% monthly logo churn. - Team: 38% of customers, $2.85M ARR, $99/month for up to 20 seats, average 11 active seats, 1.5% monthly logo churn. - Business: 14% of customers, $2.40M ARR, $249/month for up to 50 seats, average 31 active seats, 0.9% monthly logo churn. - Enterprise: 4% of customers, $1.40M ARR, negotiated contracts. Enterprise pricing will not change. Proposed plans: - Core: $10 per active seat per month, 3-seat minimum. - Pro: $12 per active seat per month, 10-seat minimum. - Advanced: $14 per active seat per month, 25-seat minimum. - Annual prepayment receives two months free. - Intended mapping is Starter to Core, Team to Pro, and Business to Advanced. Management objectives and constraints: - Increase total ARR by at least 12% within 12 months. - Keep any increase in monthly logo churn below 0.4 percentage points for each cohort. - Do not change signed Enterprise contracts. - Billing engineering can support only one migration rule per legacy cohort. - Customer Success can conduct at most 180 high-touch migration calls per month. - The 120 largest Business accounts represent 52% of Business ARR. - A recent survey found that 61% of Team and Business respondents accept per-seat pricing in principle, but only 28% consider a first-year increase above 25% fair. - No reliable price-elasticity study exists. Evaluate these three policies: A. Move every non-Enterprise customer to list pricing at the next renewal. B. Grandfather all existing customers for 12 months, then move them to list pricing. C. Move customers at renewal but cap the first-year increase at 20%; apply full list pricing at the following renewal. Show the implied monthly price change for the average customer in each legacy cohort before discounts. Explain what can and cannot be concluded from those averages. Recommend one policy, including any cohort-specific migration rules that remain operationally feasible. Provide a practical exception policy, a prioritized allocation of the 180 monthly Customer Success calls, customer-communication principles, measurable stop/go thresholds, and a 90-day implementation plan. Write in direct natural language with these sections: Executive Recommendation, Cohort Economics, Policy Comparison, Migration Design, Risk Controls, and 90-Day Plan. Distinguish calculations from assumptions, avoid false precision, surface tensions with the 12% ARR objective, and identify any missing data that should be collected before final approval.

Rewrite the source material below as a participant-facing consent section for a Phase 2 rheumatoid arthritis study. This will be reviewed by an institutional review board and used during enrollment at U.S. research sites. Write for an eighth-grade reading level while preserving every material fact, number, uncertainty, and distinction between research and standard care. Use respectful, neutral language. Do not imply that the study drug is effective, minimize risks, invent safeguards, or add medical facts not supplied here. Organize the finished section under these exact headings: Why is this study being done? What will happen if I join? What are the risks and discomforts? Could I benefit? What other choices do I have? Can I leave the study? Will I be paid or charged? Define “placebo” at first use. Clearly explain the 2-to-1 random assignment in everyday language, state that neither the participant nor the study team will know the assignment during the study except when medically necessary, and distinguish research-only procedures from usual arthritis care. Use short paragraphs and bullets where they improve comprehension. Address the reader as “you.” Return only the finished consent section. SOURCE MATERIAL Purpose and design: The sponsor is evaluating RZ-417, an investigational injectable medicine, in adults with moderate-to-severe rheumatoid arthritis whose symptoms remain active despite stable methotrexate treatment. RZ-417 has not been approved by the U.S. Food and Drug Administration for rheumatoid arthritis or any other condition. Approximately 180 participants will be enrolled. Participation lasts up to 28 weeks: a screening period of up to 4 weeks, 20 weeks of study treatment, and a safety follow-up visit about 4 weeks after the final dose. Assignment and blinding: Eligible participants will be randomized in a 2:1 ratio to receive either RZ-417 or placebo by injection under the skin once every 2 weeks. Assignment is determined by chance. Participants will continue their prescribed stable dose of methotrexate. The study is double-blind. Participants, investigators, and most study personnel will not know treatment assignment unless the information is needed to manage an urgent medical problem. A placebo contains no active RZ-417. Visits and procedures: Participants will attend 11 clinic visits. Procedures include medical-history review; physical examinations; vital signs; joint examinations; questionnaires about pain, fatigue, daily activities, and quality of life; blood and urine collection; pregnancy testing when applicable; electrocardiograms at screening and Week 20; and study-drug or placebo injections. Approximately 240 mL of blood will be collected over the entire study. Some blood samples will measure study-drug levels and immune responses; these tests are for research and would not ordinarily be part of routine arthritis care. Participants will record symptoms, medications, and injection reactions in an electronic diary. Each visit is expected to last 1 to 3 hours. Known and possible risks: In earlier studies, commonly reported reactions associated with RZ-417 were injection-site pain, redness, swelling, headache, nausea, and upper respiratory infections. Because RZ-417 changes immune-system activity, it may increase susceptibility to infection. Serious infection is possible. Allergic reactions, including rare severe reactions, may occur. Long-term risks and risks that are uncommon or not yet known cannot be ruled out because the medicine is investigational. Blood draws may cause temporary pain, bruising, light-headedness, fainting, or, rarely, infection. Electrocardiogram stickers may irritate the skin. Answering questionnaires may cause boredom or emotional discomfort. Methotrexate has its own known risks, which the treating clinician will discuss separately. Reproductive precautions: The effects of RZ-417 on an embryo, fetus, or nursing infant are unknown. Participants who could become pregnant must have a negative pregnancy test before treatment and use a highly effective contraceptive method during treatment and for 12 weeks after the final dose. Participants who could father a child must use effective contraception during the same period. Pregnancy must be reported to the study team immediately. Pregnant or breastfeeding individuals cannot participate. Benefits and alternatives: Participants may or may not experience improvement. Information learned may help future patients, but no benefit is promised. Alternatives include not joining, continuing current treatment, changing approved medicines with the participant’s clinician, or joining another study if eligible. Voluntary participation and withdrawal: Participation is voluntary. Refusal will not affect access to regular medical care or benefits. Participants may leave at any time without penalty. The investigator may end participation for safety concerns, failure to follow study requirements, pregnancy, study cancellation, or other reasons allowed by the protocol. Participants who stop treatment may be asked to complete safety assessments, but they may decline. Costs and payment: The sponsor will provide RZ-417 or placebo and research-only tests at no charge. Participants or their insurers remain responsible for usual medical care, including methotrexate and treatment unrelated to the research. Participants will receive $75 for each completed clinic visit, up to $825 total. Reasonable parking or public-transit expenses will be reimbursed with receipts, up to $30 per visit.